Enzyme Replacement Therapy is One of the Popular Type of Gaucher Disease Treatment


Gaucher disease, an inherited condition affecting fewer than 10,000 people worldwide, affects the body’s lysosomal storage system. This means that a specific type of fat molecule (glucocerebrosidase) cannot be broken down correctly, causing lipid engorged cells to accumulate in various parts of the body. These cells lead to a variety of problems, including spleen and liver enlargement, anemia, excessive bleeding and bruising, bone disease, and a range of other symptoms and complications.

Symptoms: Gaucher disease treatment option focus on reducing or stopping the accumulation of glucocerebrosidase enzyme. Enzyme replacement therapy, given intravenously, can stop and often reverse the signs and symptoms of GD, allowing patients to enjoy a better quality of life. A specialized, multidisciplinary team is critical for managing care for GD. This team includes a Gaucher disease specialist, who knows how to treat GD effectively and manage symptomatic issues that may arise. They also can monitor a patient’s progress, identify and recommend treatment for early-stage complications and help the family understand how to deal with this debilitating disorder.

According to Coherent Market Insights the Gaucher Disease Treatment Market Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028.

Enzyme replacement therapy is an effective Gaucher disease treatment available for many people. This involves a modified form of the enzyme, glucocerebrosidase, administered in an IV infusion twice a week. This approach can relieve pain, prevent further bone loss and improve symptoms such as fatigue. There is also gene therapy, which involves injecting a genetically engineered version of the glucocerebrosidase gene directly into the brain or other organs.

Substrate reduction therapy is another potential treatment for glucocerebroside accumulation in patients with Gaucher disease who are not responding to enzyme replacement therapy. Currently, there are three long-term glucocerebroside substrate reduction therapies available in the US for patients with a diagnosis of Gaucher disease: imiglucerase, velaglucerase alfa, and taliglucerase alfa.

Comments

Popular posts from this blog

Linear Motion System Control Movements with Various Variables and Complication

Recent Advancement in Synthesis and Process Development Of Polyether Polyols

Food Additives have been Playing Significant Role in Enhancing Quality and Taste of the Food